# US 2025/0144190 A1 · Compositions and methods for treating central nervous system injury

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144190 A1
- Document ID: US20250144190A1
- Status: Published application
- Kind: A1
- Application number: 18/806,072
- Filed: 2024-08-15
- Published: 2025-05-08
- Earliest claimed: 2016-10-17
- Assignees: MUSC Foundation for Research Development; The United States Government AS Represented By the Department of Veteran Affairs
- Applicants: MUSC Foundation For Research Development; United States Government as Represented by the Department of Veteran Affairs
- Inventors: Stephen Tomlinson; DeAnna Adkins; Ali Alawieh
- Web page: https://patentgrep.com/patent/US20250144190A1

## CPC

- A61K 38/57: from animals; from humans {(A61K38/553, A61K38/556 take precedence)}
- A61K 38/1709: {from mammals}
- A61K 38/1725: {Complement proteins, e.g. anaphylatoxin, C3a or C5a}
- A61K 38/49: Urokinase; Tissue plasminogen activator
- A61P 25/00: Drugs for disorders of the nervous system
- C07K 16/18: against material from animals or humans
- A61K 2039/505: {comprising antibodies}
- C07K 2317/622: Single chain antibody (scFv)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present invention describes compositions and method for improving outcomes after injury to the central nervous system wherein complement signaling is activated. In one aspect, the method comprises administering to a subject a therapeutically effective amount of a therapeutic agent comprising a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement, and wherein therapeutic agent is administered in combination with rehabilitation therapy or thrombolytic agent.

## Claims

### Claim 1

A kit for treating central nervous system injury comprising
(a) a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement signaling, and
(b) a thrombolytic agent.

### Claim 2 (depends on 1)

The kit of claim 1 wherein:
(i) the targeting portion comprises an antibody or fragment thereof that specifically binds to Annexin IV, a post-translational modification found on Annexin IV and other proteins, or a phospholipid;
(ii) the inhibitor portion comprises at least one, or a fragment thereof, selected from the group consisting of FH, DAF, MCP, CD59, Crry, MAp44, and CR1; and/or
(iii) the thrombolytic agent is t-PA.

### Claim at position 3

-4. (canceled)

### Claim 5

A method for decreasing neurological deficit after central nervous system injury in a subject comprising
(a) administering to the subject a therapeutically effective amount of a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement signaling, and
(b) providing rehabilitation therapy to the subject.

### Claim 6 (depends on 5)

A method of claim 5 wherein the injury is ischemic stroke.

### Claim 7 (depends on 5)

A method of claim 5 wherein the injury is traumatic brain injury.

### Claim 8 (depends on 5)

A method of claim 5 wherein the injury is spinal cord injury.

### Claim 9 (depends on 5)

The method of claim 5 wherein the targeting portion comprises an antibody or fragment thereof that specifically binds to Annexin IV, a post-translational modification found on Annexin IV and other proteins, or a phospholipid.

### Claim 10 (depends on 5)

A method of claim 5 wherein the inhibitor portion comprises at least one selected from the group consisting of FH, DAF, MCP, CD59, Crry, MAp44, and CR1.

### Claim 11 (depends on 5)

A method of claim 5, wherein the rehabilitation therapy comprises at least one therapy selected from the group consisting of cognitive and motor therapy.

### Claim 12

A method for improving memory retention after central nervous system injury in a subject comprising
(a) administering to the subject a therapeutically effective amount of a targeted inhibitor molecule comprising a targeting portion and an inhibitor portion, wherein the molecule inhibits complement signaling, and
(b) administering to the subject a composition comprising a thrombolytic agent.

### Claim 13 (depends on 12)

A method of claim 12 wherein the injury is ischemic stroke.

### Claim 14 (depends on 12)

A method of claim 12 wherein the injury is traumatic brain injury.

### Claim 15 (depends on 12)

The method of claim 12 wherein the injury is spinal cord injury.

### Claim 16 (depends on 12)

The method of claim 12 wherein the targeting portion comprises an antibody or fragment thereof that specifically binds to Annexin IV, a post-translational modification found on Annexin IV and other proteins, or a phospholipid.

### Claim 17 (depends on 12)

A method of claim 12 wherein the inhibitor portion comprises at least one selected from the group consisting of FH, DAF, MCP, CD59, Crry, MAp44, and CR1.

### Claim 18 (depends on 12)

A method of claim 12, wherein the thrombolytic agent is t-PA.

### Claim 19 (depends on 5)

The method of claim 5, wherein administration of the targeted inhibitor molecule and the thrombolytic agent are simultaneous or staggered.

### Claim 20 (depends on 12)

The method of claim 12, wherein administration of the targeted inhibitor molecule and the thrombolytic agent are simultaneous or staggered.
